Check for updates

OPEN ACCESS

EDITED BY Weijian Bei, Guangdong Metabolic Disease Research Center of Integrated Chinese and Western Medicine, China

REVIEWED BY Joanna Gdula-Argasinska, Jagiellonian University Medical College, Poland Kai Wang, Chinese Academy of Agricultural Sciences (CAAS), China Yan Yan, Shanxi University, China Runhui Liu, Second Military Medical University, China

*CORRESPONDENCE Hui Liao, ⊠ huiliao@263.net Rongshan Li, ⊠ rongshanli@126.com

[†]These authors have contributed equally to this work and share first authorship

RECEIVED 02 May 2024 ACCEPTED 06 August 2024 PUBLISHED 21 August 2024

CITATION

Han Z, Gong L, Xue Y, Wang R, Liu J, Wang X, Zhao W, Liao H and Li R (2024) Effects of *Inonotus obliquus* on ameliorating podocyte injury in ORG mice through TNF pathway and prediction of active compounds. *Front. Pharmacol.* 15:1426917. doi: 10.3389/fphar.2024.1426917

COPYRIGHT

© 2024 Han, Gong, Xue, Wang, Liu, Wang, Zhao, Liao and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Effects of *Inonotus obliquus* on ameliorating podocyte injury in ORG mice through TNF pathway and prediction of active compounds

Zhaodi Han^{1†}, Le Gong^{2†}, Yani Xue², Rui Wang², Jing Liu², Xinyu Wang², Wenyan Zhao², Hui Liao^{1*} and Rongshan Li^{3*}

¹Drug Clinical Trial Institution, Shanxi Provincial People's Hospital Affiliated to Shanxi Medical University, Taiyuan, China, ²School of Pharmacy, Shanxi Medical University, Taiyuan, China, ³Department of Nephrology, Shanxi Provincial People's Hospital Affiliated to Shanxi Medical University, Taiyuan, China

Background: Podocyte injury is a common pathologic mechanism in diabetic kidney disease (DKD) and obesity-related glomerulopathy (ORG). Our previous study confirmed that *Inonotus obliquus* (IO) improved podocyte injury on DKD rats. The current study explored the pharmacological effects, related mechanisms and possible active components of IO on ORG mice.

Methods: Firstly, by combining ultra-high performance liquid chromatography tandem mass spectrometry analysis (UPLC-Q-TOF-MS) with network pharmacology to construct the human protein-protein interaction mechanism and enrich the pathway, which led to discover the crucial mechanism of IO against ORG. Then, ORG mice were established by high-fat diet and biochemical assays, histopathology, and Western blot were used to explore the effects of IO on obesity and podocyte injury. Finally, network pharmacology-based findings were confirmed by immunohistochemistry. The compositions of IO absorbed in mice plasma were analyzed by UPLC-Q-TOF-MS and molecular docking was used to predict the possible active compounds.

Results: The network pharmacology result suggested that IO alleviated the inflammatory response of ORG by modulating TNF signal. The 20-week *in vivo* experiment confirmed that IO improved glomerular hypertrophy, podocyte injury under electron microscopy, renal nephrin, synaptopodin, TNF- α and IL-6 expressions with Western blotting and immunohistochemical staining. Other indicators of ORG such as body weight, kidney weight, serum total cholesterol, liver triglyceride also improved by IO intervention. The components analysis showed that triterpenoids, including inoterpene F and trametenolic acid, might be the pharmacodynamic basis.

Conclusion: The research based on UPLC-Q-TOF-MS analysis, network pharmacology and *in vivo* experiment suggested that the amelioration of IO on podocyte injury in ORG mice via its modulation on TNF signal. Triterpenoids were predicated as acting components.

KEYWORDS

Inonotus obliquus, obesity-related glomerulopathy, podocyte injury, TNF signal, triterpenoids

1 Introduction

Inonotus obliquus (IO) is a white rot fungus that has been used in traditional medicine for centuries, especially in Russia and northeastern China (Hao et al., 2023). Studies have shown that the main components of IO include triterpenoids, flavonoids, organic acids, polyphenols and alkaloids and other compounds, which have antioxidant, anti-inflammatory, hypoglycemic and other pharmacological effects (Ren et al., 2018; Anwaier et al., 2020). And, the diverse bioactive compounds confer IO great potential to inhibit podocyte injury and improve renal function (Duan et al., 2022). Our previous literature study showed that IO has been studied predominantly on cancer area, followed by diabetes mellitus and its complications (Shen et al., 2022). We further confirmed that IO delays the development of proteinuria in type 2 diabetic kidney disease (DKD) rat model through hypoglycemic, hypolipidemic, improving renal hemodynamics and other related effects (Zhang et al., 2022).

Podocyte injury in the glomerulus is central to the development of proteinuria in various chronic kidney diseases, including DKD (Liu S. et al., 2022), obesity-related glomerulopathy (ORG) (Wei et al., 2021), etc. Unlike DKD, which is clinically characterized by persistent hyperglycemia, obesity is recognized as an independent risk factor for the development of ORG (Sandino et al., 2022). Weight loss and proteinuria reduction are obviously the key to treat ORG (Mangat et al., 2023). Our previous work confirmed that amelioration of IO on proteinuria in DKD rats is associated with its reduction in podocyte injury, and we also observed that IO has a role in reducing body weight (BW) in DKD rats (Zhang et al., 2022). Based on our previous studies, we hypothesized that IO might have a protective effect for ORG.

Before performing an *in vivo* study on the above hypotheses, we first analyzed the possible mechanisms by which the components contained in IO intervene in ORG. As a useful tool, network pharmacology is believed to achieve a comprehensive insight into the therapeutical mechanism of multi-compound traditional medicine (Hao et al., 2023). Network pharmacology integrates cheminformatics, network topology and omics data, to holistically elucidate drug mechanisms (Muthuramalingam et al., 2023). Although studies have been conducted using a network pharmacology approach to investigate the mechanism of action of IO in the treatment of other diseases, there are still some limitations (Liu et al., 2021). One such limitation is that the information of IO components is derived from databases and published literature, which may not fully represent the complex of the real ingredient system.

Ultra-performance liquid chromatography coupled with electrospray tandem mass spectrometry (UPLC-Q-TOF-MS) is used in the qualitative and quantitative analysis of complex ingredient systems due to its powerful functions and wide applicability (Jiang et al., 2023). UPLC utilizes micron-sized stationary phases and higher column pressures to dramatically increase separation efficiency (Yang et al., 2024). ESI-Triple TOF MS/MS could perform multi-stage mass spectrometry detection of the target compounds to provide rich structural and quantitative information (Shu et al., 2023; Xue et al., 2024). Online mass spectrometry databases, such as Massbank, mzClound, could identify and confirm the components separated and detected by

UPLC-Q-TOF-MS (Song et al., 2022). The integrated application of these techniques in this manuscript provided the basis for conducting component analysis, absorption, metabolism, and mechanism of IO.

A human protein-protein interactome (PPI) network for IO against ORG was constructed by integrating UPLC-Q-TOF-MS profiling and databases searching. Moreover, through network analysis for PPI and pathway enrichment, the key pathway and targets were focused. Subsequently, it was validated by establishing an ORG mice model and measuring BW, triglyceride (TG), total cholesterol (TC), renal function and podocyte protein expression after intervention with IO. Afterwards, the absorbed into blood components of IO were analyzed by UPLC-Q-TOF-MS, and combined with the results of network pharmacology, the pharmacodynamic components were proposed and verified by molecular docking. This provided a novel strategy for discovering the mechanism and active compounds of IO alleviating ORG.

2 Material and methods

2.1 Chemicals and reagents

IO was collected from Huzhong National Nature Reserve of the Greater Khingan Mountains in Heilongjiang Province. The traits of IO used in this study were spherical, oblate, or irregular mass, varying in size, 25–40 cm in diameter, sessile, and with a verrucose protrusion on the surface. The outer surface is gray-black with irregular deep furrowed wrinkled texture. The texture is hard, the outer layer of the section is thin, about 5 mm thick, dark brown, and the flesh is yellow to yellow-brown. The odor is slight, and the taste is slightly sweet. IO used in this study was identified as *"Inonotus obliquus* (Ach. ex Pers.) Pilát" (Dai and Li, 2011) by Professor Shang Guo (Shanxi Institute for Functional Food, Shanxi Agricultural University, Taiyuan, China).

Ordinary diet and high-fat-diet (HFD) were obtained from Boaigang Biotechnology Company (Beijing, China). The ordinary diet consists of 67.4% of calories from carbohydrates, 20.6% from protein and 12% from fat, and the HFD is 60% of calories from fat, 20% from protein and 20% from carbohydrates. The analytical grade organic solvents, such as methanol and acetonitrile, were bought from Thermo Fisher Scientific (USA).

2.2 Preparation of IO extracts and qualitative analysis by UPLC-Q-TOF-MS

The preparation of IO extracts was detailed in our previous study (Zhang et al., 2022). The sample of IO extract was mixed with 50% methanol-acetonitrile (1:10, w/v) and then ultrasonicated for 30 min. After sonication, the mixed sample was centrifuged (17,000 g, 15 min, 20°C) and the supernatant was taken in an EP tube which was then dried by vacuum at 35°C. The 100 μ L of 50% methanol-water was added to the dried sample. After vortexing and centrifuging, the supernatant was analyzed by an UPLC system (Shimadzu, JPN).

The chromatographic separation was carried out on Waters XS elect HSS T3 XP column (2.1 \times 100 mm, 1.8 μm , United States) with the mobile phase composed of 0.1% formic acid in water and 0.1% formic acid in acetonitrile under gradient elution. The AB 5600 Triple TOF mass spectrometer (AB SCIEX, United States) was capable of primary and secondary mass spectrometry data acquisition based on IDA functionality under Analyst TF 1.7, AB Sciex software control. In each acquisition cycle, the molecular ions with the maximum intensity and over 100 were selected for the acquisition of the corresponding secondary mass spectrometry data. MS detection range was m/z 50–1,200; electrospray bombardment energy was 30 eV; secondary mass spectra were acquired every 50 m. The ESI settings were as follows: gas pressure: 60 Psi; auxiliary air pressure: 60 Psi; capillary temperature, 350°C; in positive ion mode: spray voltage, 5 kV; in negative ion mode: spray voltage, 4 kV (Han et al., 2022).

The composition of the precursor and fragment ions were processed and sequenced by Analyst TF 1.7 software. After the data were converted to mzML format by Proteowizard software, MS-DIAL software was utilized for peak identification, peak filtration, and peak alignment, to obtain the data matrix, including m/z, intensity and retention time. Components identification was first confirmed on the basis of accurate molecular weight ($\Delta \leq 30$ ppm) and then further validation was based on the secondary mass spectrometry database (Massbank, GNPS, mzClound, etc.) as well as a self-constructed library of IO components constructed from previously published papers.

2.3 Collection of IO potential targets

The SMILE formula of IO components was imported into the SwissTargetPrediction platform (http://www.swisstargetprediction. ch) (Daina and Zoete, 2024), the species was set as "*Homo sapiens*" and the probability was set as "> 0.1." Then the corresponding targets of IO components were obtained. The protein knowledgebase Uniprot (http://www.uniprot.org/) was employed to standardize the targets with restrict species setting as "*H. sapiens*." The duplicate targets among the components were removed and potential targets of IO were obtained at last.

2.4 Collection of ORG therapeutic targets

The ORG therapeutic targets were assembled from a human gene database GeneCards (https://www.genecards.org/) (Stelzer et al., 2016), a database of online mendelian inheritance in man OMIM (https://www.omim.org) (McKusick, 2007) and a database of gene-disease associations DisGeNET (https://www.disgenet.org) (Piñero et al., 2020). In the above three databases, targets were obtained by searching the keywords "obesity-related glomerulopathy." All the targets were pooled together and also standardized according to the information in Uniprot.

2.5 Collection of IO against ORG targets

The targets obtained in 2.3 and 2.4 were intercrossed by Bioinformatics & Evolutionary Genomics (https://bioinformatics. psb.ugent.be/webtools/Venn/) platform, and the therapeutic targets of IO components for ORG diseases were obtained.

2.6 Construction of PPI network

The targets obtained in 2.5 were uploaded into String database (https://cn.string-db.org/) (Szklarczyk et al., 2023). The species were also set as "*H. sapiens*" and the protein interaction score was set as "0.4." Finally, the target interaction relationships under the human PPI background network were obtained. The results were imported into Cytoscape 3.8.2 software to construct the corresponding PPIs and the degree value of the target was calculated.

2.7 Pathway enrichment analysis

The targets obtained in 2.5 were subjected to Gene Ontology (GO) biological process (BP) enrichment analysis and signaling pathway Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis using the Enrichr (https://maayanlab.cloud/ Enrichr/) (Chen et al., 2013; Kuleshov et al., 2016; Xie et al., 2021), followed by visualization and analysis through the bioinformatics platform (https://www.bioinformatics.com.cn/) (Tang et al., 2023).

2.8 Animal experiments of IO treatment for ORG mice

Male C57BL/6J mice (4 weeks old) were purchased from Shanxi Provincial Key Laboratory of Nephrology and the Laboratory Animal Center (Taiyuan, China) and kept under specific pathogen free conditions (12-h light/dark cycle, $25^{\circ}C \pm 2^{\circ}C$) with free access to food and water. Animal experiments was approved by the Ethics Review Committee for Animal Experimentation of Shanxi Provincial People's Hospital (Approval No. 2021-306). Animals were randomized divided into two groups after 1 week of acclimatization feeding: normal control group (CON with ordinary food, n = 6) and obesity model group (with HFD, n = 18).

The mice were weighed once a week. The model mouse was recognized to be obesity when its body weight ratio (BWR) exceeded 20% of CON in the same week (Wang Y. et al., 2023).

The BWR (%) = $\frac{\text{The BW of mouse} - \text{The average BW of CON group}}{\text{The average BW of CON group}} \times 100$

Next, the obesity model group was randomly divided into three groups: the ORG model group (ORG, n = 6), the IO low-dose group (IO_L, n = 6), and the IO high-dose group (IO_H, n = 6). The mice in ORG group, IO_L group and IO_H group were continued to be fed with HFD until the end of the experiment. In addition, the mice in IO_L group and IO_H group were given IO extracts by gavage in a dose of 75 mg/kg/day and 150 mg/kg/day separately, for 12 consecutive weeks.

After the above four groups were identified, 24 h urine was collected and recorded from each group of mice by metabolic cages at weeks 7, 10, 12, 16, and 20, and the concentration of urinary proteins was determined by the Coomassie Brilliant Blue method. At week 18, intraperitoneal glucose tolerance test (IPGTT) and insulin tolerance test (IPITT) assays were performed (More details are provided in Supplementary Methods.



At the end of the experiment, blood, bilateral kidney and liver tissues were taken. Blood was centrifuged (3,000 rpm, 15 min, 4°C) to obtain serum, which were used to measure the levels of fasting blood glucose (FBG), serum creatinine (SCr), blood urea nitrogen (BUN) (Jiangsu Meimian Industrial Co. Ltd., China) and TC (Nanjing Jiancheng Bioengineering Institute, China). Liver tissues were used for histopathological examination and homogenized for determination of TG content with GPO-PAP kit assay (Nanjing Jiancheng Bioengineering Institute, China). Kidney tissues were weighed and used for histopathological examination and Western blot experiments.

2.9 Pathological examination

2.9.1 Light microscopy

Freshly dissected renal and liver tissues were fixed in 10% neutral formalin buffer and embedded in paraffin. The embedded tissues were

cut into 3 µm thick sections with Leica Microtome. The renal sections were stained with periodic acid-schiff (PAS) and Hematoxylin & Eosin (HE), and liver sections with oil red O reagent, separately. The morphological changes of glomerulus were observed with KF-PRO-005-EX digital scanner (Motic, Xiamen, China).

The images were selected randomly in which the glomerulus number was no more than twenty and were analyzed with K-Viewer (1.5.3.1) image analysis software (×400, KFMI, China). The length of the two longest perpendicular diameters in each glomerular capillary tuft without Bowman's space was measured in μ m, and then the mean value was calculated from 10 images. The areas of the glomerular mesangial region and capillary tuft were measured. The relative area of the mesangial region (%) was calculated according to the formula (Zhang et al., 2022).

The relative area (%) =
$$\frac{\text{Area of the mesangial region}}{\text{Area of the capillary tuft}} \times 100$$

2.9.2 Electron microscopy

Freshly dissected kidneys were fixed using 2.5% glutaraldehyde. The ultrathin sections were stained with uranium acetate-lead citrate for electron microscopy. For each specimen, ten photographs (\times 20,000 magnification) covering different regions in the glomerular cross section were taken separately.

The thickness of glomerular basement membrane (GBM) and the width of glomerular foot process (GFP) were all measured. Images were selected and analyzed using the RADIUS Control & Imaging software (EMSIS ASIA, Germany).

2.10 Western blot

Renal tissues (about 20 mg) were homogenized with lysis buffer (1:10, w/v) containing protease inhibitors. After centrifugation at 12,000 rpm for 10 min at 4°C, the supernatants were collected and protein levels were determined using the BCA protein assay kit (Epizyme Biotech, Shanghai, China). Proteins were separated by 10% SDS-PAGE and then transferred to a PVDF membrane. Membranes were blocked with protein free rapid blocking buffer (Epizyme Biotech, Shanghai, China) for 20 min and probed with primary antibodies overnight at 4°C, including Nephrin (Abcam, United States) and Synaptopodin (Proteintech, China). GAPDH (Abways, China) was used as loading control. After the membrane was washed with TBST three times, it was incubated with HRP-conjugated anti-rabbit antibody for 60 min at room temperature. The bands were visualized by Tanon (Shanghai, China) after using a chemiluminescence reagent.

2.11 Immunohistochemistry

Renal tissues were fixed in 10% buffered formalin for 3 days, embedded in paraffin and then sectioned at a thickness of 4 mm. After deparaffinization, antigen retrieval and blocking with goat serum, the section was incubating with anti-IL-6 or anti-TNF- α rabbit polyclonal antibodies (Servicebio, Wuhan, China) overnight at 4°C. After washed with PBS, the sections were incubated with HRP-conjugated goat anti-rabbit IgG secondary antibody

(Servicebio, Wuhan, China) and the peroxidase reaction was developed with diaminobenzidine (Servicebio, Wuhan, China). Subsequently, the sections were counterstained with hematoxylin, and the images were captured using an inverted microscope.

2.12 Animal experiments of IO components absorbed into blood

Three 8-week-old C57BL/6J male mice, weighing (24.6 \pm 1.0) g, were acclimatized and fed for 1 week, and then the mice were administered with IO at 300 mg/kg by gavage, the maximum dose available, twice a day for 3 days. The mice were anesthetized and the blood was taken from the eye socket within 1 hour of the last administration. The three blood samples were centrifuged separately for 10 min at 4°C, 3,000 rpm, and then the supernatants were mixed well as drug-containing serum.

The 400 μ L drug-containing serum was add with 600 μ L of methanol and centrifuged at 17,000 g for 15 min at 4°C. The supernatant was taken and dried under vacuum. The dried sample was dissolved in 100 μ L methanol (50%, in water). After vortexing, the supernatant was analyzed by an UPLC system (Shimadzu, JPN). Chromatographic separation and mass spectrometric methods were performed as in 2.2.

2.13 Molecular docking

The 3D structure information of IO against ORG compounds we obtained in PubChem. Then, the 3D structure information of the target protein (TNF- α and IL-6) was obtained in PDB database. The structures of large molecule target proteins and small molecule compounds were imported in CB-DOCK2 website (https://cadd. labshare.cn/cb-dock2/php/index.php) (Liu Y. et al., 2022) for virtual molecular docking.

2.14 Statistical analysis

Measurement data were expressed as mean \pm standard deviation ($\bar{X} \pm$ SD). The comparison of sample means between the two groups was performed using the independent samples *t*-test. The difference between the two groups was considered statistically significant at p < 0.05.

3 Results

3.1 Construction of PPI network

The flowchart of network pharmacology and UPLC-Q-TOF-MS integrated strategy, to reveal the mechanism of IO against ORG, was shown in Figure 1A. A total of 146 components were identified in the IO using UPLC-Q-TOF-MS analysis (Supplementary Table S1). The total ion flow diagram of IO extracts was presented in Supplementary Figure S1.

The structural formulae of the 146 components obtained from UPLC-Q-TOF-MS profiling analysis were imported into the SwissTargetPrediction database for the prediction of targets.

There are 5,378 possible potential targets corresponding to 115 components, but no potential targets for the other 31 components. After de-duplication and harmonization of Uniprot IDs, 899 potential targets were finally obtained.

By searching in the disease-target platform, 189, 16, and 187 therapeutic targets for ORG were collected from GeneCards, DisGeNET and OMIM databases, respectively. Then, the results of the three databases were merged, and a total of 377 ORG therapeutic targets were obtained (Figure 1B). Only 72 key targets from the intersection of 899 IO potential targets with 377 ORG therapeutic targets were kept (Figure 1C).

The PPI network of 72 key targets was constructed, which had 72 nodes and 1236 edges with an average degree of 34.3. Among them, 31 core targets, such as IL-6, TNF, AKT1, STAT3, and PPARG, were greater than the average degree value (Supplementary Table S2). The results suggested that core targets, such as IL-6 and TNF, played key regulatory roles in the PPI network of 72 targets for IO against ORG (Figure 1D).

3.2 Enrichment analysis of the key regulation pathway for IO against ORG

KEGG and GO_BP pathway enrichment analysis was performed on the 72 key targets. In Figure 2A, GO_BP pathway enrichment analysis revealed that pathways regulating inflammatory response were significantly enriched, e.g., inflammatory response to wounding and positive regulation of cytokine production involved in inflammatory response.

Moreover, by performing targets analysis on the enriched pathways, we found that TNF and IL-6 involved in four pathways associated with inflammation. They were inflammatory response to wounding, negative regulation of lipid localization, positive regulation of leukocyte adhesion to vascular endothelial cell and positive regulation of cytokine production involved in inflammatory response (Figure 2B).

The KEGG pathway enrichment analysis suggested that the treatment mechanism of IO for ORG might be related to TNF signaling pathway, HIF-1 signaling pathway and the pathways of glycolipid metabolism, such as AGE-RAGE signaling pathway in diabetic complications and lipid and atherosclerosis (Figure 2C).

Further categorization of the pathways with top 15 combined scores showed that HIF-1 and TNF signaling pathways were key regulatory pathways in the environmental information processing classification (Figure 2D). Combined with the results of PPI, the mechanism may be related to the regulation of TNF and IL-6 in the TNF signaling pathway.

3.3 Improvement of IO on obesity-related biological parameters

3.3.1 Improvement of IO on obesity

The flowchart of animal experiments was shown in Figure 3A. From week 0 to week 20, the results of BW of the different groups were shown in Figure 3B. From week 4 to the end of the experiment, the BW of the model group, measured weekly, increased significantly compared to that of the CON group (all: p < 0.05).

At week 8, the model group gained 20% more BW than the CON group (BWR >20%), at which time point the obesity modeling was

considered to be established (Wang Y. N. et al., 2023). As shown in Figure 3C, from week 8 to week 20, the BWR values between the model and CON groups were all higher than 20% and gradually increased with feeding time. At week 20, the BWR value in the model group increased to 79.9%, which was significantly higher than the BWR value in the IO_H group (p < 0.01).

Body weight gain (BWG) is another calculated indicator to assess the obesity of the same experimental group with feeding time (Han et al., 2023). The BWG of each experimental group was calculated as follows.

The BWG
$$(g) = ($$
The average BW at week 20 $)$
- (The average BW at week 0 $)$

We could see in Figure 3D that the BWG from week 0 to week 20 of the ORG group was significantly higher than the CON group (p < 0.001). After IO intervention, the BWG of the mice in the IO_L and IO_H group was significantly reduced when compared to the ORG group (IO_L: p = 0.029; IO_H: p < 0.001).

3.3.2 Improvement of IO on kidney weight

The results of kidney weight were shown in Figure 3E. The kidney weight was significantly increased in the ORG group compared with the CON group (p < 0.001). After IO intervention, the IO_H group was not only significantly reduced compared with the ORG group (p < 0.001) and the IO_L group (p = 0.004) separately, but also not statistically different from the CON group (P = ns).

3.3.3 Improvement of IO on hepatic TG and serum TC

As shown in Figure 3F, the ORG mice had the highest hepatic TG content, and the differences were statistically significant compared to the CON group (p = 0.040), IO_L administration (p = 0.037) and IO_H administration (p = 0.035). The CON group, IO_L group and IO_H did not show any significant difference (Three: P = ns). The results of oil red O staining on liver tissue also had the same trend (Supplementary Figure S2).

Serum TC level is a commonly used clinical index for the diagnosis of hyperlipidemia (Yin et al., 2023). As shown in Figure 3G, serum TC was significantly elevated in the ORG group compared to the CON group (p < 0.001). Serum TC in the IO_H group decreased statistically compared with the ORG group (p = 0.005).

3.3.4 Improvement of IO on FBG, IPGTT, and IPITT

At 20th week, the FBG levels of the mice in each group were shown in Figure 3H. FBG level was elevated in the ORG group after HFD feeding but was not significantly different from the CON group (P = ns), which is consistent with the clinical diagnosis of ORG (Yang et al., 2024).

Notably, FBG levels were significantly lower in both the IO_L and IO_H groups when they compared to the ORG group and the CON group separately (four: p < 0.05), but the lowered FBG still remained within the normal range.

As shown in Supplementary Figure S3, the results of IPGTT and IPITT assay also indicated the beneficial effect of IO on glucose metabolism in the model group.



following are database name abbreviations: VEC: vascular endothelial cell; PTG: prostaglandin; KSHV: kaposi sarcoma-associated herpesvirus; HCMV: human cytomegalovirus; VEGF: vascular endothelial growth factor; TLR: toll-like receptor; CLR: C-type lectin receptor.

3.4 Improvement of IO on renal function and pathological examination

3.4.1 Improvement of IO on BUN, SCr and urinary protein

The results of BUN and SCr were shown in Supplementary Figure S4. There was no significant difference in BUN and SCr between the CON and ORG group. The trends of the IO_H group and the IO_L group on BUN and SCr level were similar as FBG level. The results of 24-h urine protein of mice in each group were shown in Figure 4A. The 24-h urine protein of the ORG group significantly increased at week 10 and week 12 when compared to the CON group at same testing time (p < 0.05), however, at week 16 and week 20, there was no significant difference between the above two groups. At the four monitoring points from week 10 to week 20, 24-h urinary protein was significantly reduced in the IO_H group compared to the ORG group (p < 0.05).



FIGURE 3

Effects of IO on HFD-induced obesity and obesity-related biological parameters. (A) Flowchart of animal experiments. (B) Body weight. p < 0.05: ORG vs. CON from week 4 to week 20. (C) Body weight ratio. (D) Body weight gain. (E) Kidney weight. (F) Levels of liver TG. (G) Levels of serum TC. (H) Levels of FBG. HFD: high-fat-diet; CON: the control group; ORG: the obesity-related glomerulopathy model; IO_L: the model group treated with *Inonotus obliquus* (75 mg/kg/day); IO_H: the model group treated with *I. obliquus* (150 mg/kg/day); BW: body weight; BWR: body weight ratio; BWG: body weight gain; TG: triglyceride; TC: total cholesterol; SCr: serum creatinine; BUN: blood urea nitrogen; FBG: fasting blood glucose. Data were presented as mean \pm SD. "p < 0.05 vs. the CON; *p < 0.05 vs. the ORG.



glomerulus (PAS staining, × 400). (C) Mesangial relative area. (D) Glomerular diameter. (E) Electron microscopic images of podocyte GBM and GFP (x20,000). (F) Thickness of GBM. (G) Width of GFP. Red arrow: glomerular basement membrane; Black arrow: glomerular mesangial matrix. GBM: glomerular basement membrane; GFP: glomerular foot process; CON: the control group; ORG: the obesity-related glomerulopathy model; IO_L: the model group treated with *Inonotus obliquus* (75 mg/kg/day); IO_H: the model group treated with *I. obliquus* (150 mg/kg/day). Data were presented as mean \pm SD. #p < 0.05 vs. the CON; *p < 0.05 vs. the ORG.

3.4.2 Improvement of IO on pathological examination

As shown in Figure 4B, PAS staining showed glomerular hypertrophy in the ORG group, which was improved by the administration of IO.

Figures 4C,D showed the results of mesangial relative area and glomerular diameter of the four groups. Compared with the CON group, the ORG group had significantly increased mesangial relative area and glomerular diameter (two: p < 0.001). After 12 weeks of IO intervention, the glomerular diameter and the mesangial relative area were significantly improved compared with those in the ORG group (all: p < 0.001) and had no significant difference with the CON group (all: P = ns).

The results of HE staining also revealed the pathological changes in the glomerulus of the mice in each group, which were consistent with those of PAS staining (Supplementary Figure S5).

As shown in Figure 4E, the foot process in the CON group were arranged in an orderly manner, uniform in size. While in the ORG group, fusion of foot process could be observed, and it was also accompanied by apoptosis of

podocytes. In the IO_L and IO_H groups, significant improvement could be seen.

In Figures 4F,G, the thickness of GBM and the width of GFP were significantly increased in the ORG group compared with the CON group (p < 0.05). The thickness of GBM and the width of GFP were significantly improved in the IO_L and IO_H groups compared with the ORG group (all: p < 0.001). Figure 4G also showed that the GFP widths of IO_L and IO_H were not significantly different from the CON group (P = ns).

3.5 Improvement of IO on podocyte specific proteins in ORG mice

Figure 5 showed that the protein expressions of nephrin and synaptopodin were significantly decreased in the ORG group compared to the CON group (p < 0.05). After 12 weeks of IO intervention, the two podocyte specific protein expressions in IO_L and IO_H group were significantly increased when compared to the ORG group (p < 0.05).



The protein expressions of renal nephrin and synaptopodin. CON: the control group; ORG: the obesity-related glomerulopathy group; IO_L: the model group treated with *Inonotus obliquus* (75 mg/kg/day); IO_H: the model group treated with *I. obliquus* (150 mg/kg/day). Data were presented as mean \pm SD. #p < 0.05 vs. the CON; *p < 0.05 vs. the ORG.

Also of interest was that after IO intervention in the high dose, nephrin did not differ from the CON group (P = ns), whereas synaptopodin was significantly better than the CON (p = 0.027).

3.6 Regulation of IO on TNF- α and IL-6 levels in ORG mice

The immunohistochemical staining results of TNF- α and IL-6 in the kidney tissue were shown in Figure 6. We could see that the expression levels of TNF- α and IL-6 were significantly higher in the ORG group compared with the CON group (p < 0.05).

After 12 weeks intervention with IO, both TNF- α and IL-6 level in the two IO groups improved significantly compared to the model (p < 0.05), but only TNF- α level showed a dose-dependent manner (p < 0.05).

3.7 The compounds of IO absorbed into blood for ORG treatment

The flowchart of network pharmacology and UPLC-Q-TOF-MS integrated strategy to explore the active compounds of IO against ORG was shown in Figure 7A. The preparation of drug-containing serum in mice was shown in Figure 7B. UPLC-Q-TOF-MS analysis showed that there were 146 compounds in the IO extracts, of which 43 compounds were absorbed as prototypes and 10 compounds as their own metabolites (Figure 7C; Supplementary Table S3). The mass spectrometry spectrum was shown in Supplementary Figure S6.

Small molecules typically exert their bioactive effects through interactions with protein targets. In order to identify the interaction between the 72 key targets of IO against ORG and IO compounds, a "compounds-targets network" was established in Figure 7D. The compounds-targets network contained 72 key targets and 86 potential active compounds, and 513 compound-target interactions were generated. As shown in Figure 8A, only 23 common compounds from the intersection of 45 absorbed compounds of the IO extracts with 86 potential compounds from network analysis were kept. Among the 23 active compounds, there were 10 triterpenoid components, which accounted for the largest share of 43.48% (Figure 8B). These results indicated that triterpenoid components, such as inoterpene F and trametenolic acid, were active compounds in the regulation of TNF- α and IL-6.

3.8 Validation of triterpenoids on TNF signaling pathway

The binding energy of molecular docking indicates the energy value of receptor-ligand docking, and the smaller the value, the greater the affinity of the ligand-receptor binding and the more stable the conformation (Figure 8C). Inoterpene F and trametenolic acid are two kinds of triterpenoid monomers extracted from IO by our research group (Hao, 2023). The binding energy of inoterpene F was -7.1 kcal/mol with TNF- α and -6.9 kcal/mol with IL-6; the binding energy of trametenolic acid was -6.9 kcal/mol with TNF- α and -7.0 kcal/mol with IL-6 (Figure 8D). These results confirmed that the triterpenoid components of IO extracts could directly bind to TNF- α and IL-6, to regulate the inflammatory signaling pathway, and improve the ORG.

3.9 Prediction of the active components based on network pharmacology

Among the 146 components of the IO extracts, there were 48 terpenoids, including 36 triterpenoids, accounting for about 24.66% (Figure 9A). Among the 43 components of IO absorbed into blood, there were 12 triterpenoids, accounting for 27.91%



(Figure 9B). Combining the results of network analysis and molecular docking, it is obvious that the triterpenoid compounds of IO was not only the main compounds but also the active components.

4 Discussion

Currently, obesity is increasing worldwide at an alarming rate. Obesity increases the risk of many chronic diseases, such as type 2 diabetes, coronary heart disease, and also ORG. The prevalence of ORG is increasing in parallel with the worldwide obesity epidemic. The body mass index and waist circumference are used a lot to classify obesity in clinical medicine (Nimptsch et al., 2019). The obesity mice model could be verified based on BW (Ren et al., 2022), BWG (Han et al., 2023) and BWR (Wang Y. et al., 2023) which were all observed in our study. Rodent models have been widely used to elucidate the pathophysiology of obesity with success for decades, but how to define obesity in rat or mouse rodent models remains ambiguous, just like lacking a globally accepted definition of obesity in human (Vecchié et al., 2018). In this case, three indicators, BW, BWR and BWG, were used to determine the degree of obesity in a comprehensive manner.

After 4 weeks of HFD feeding, the BW between the model and the normal showed a significant difference, which lasted until 8 weeks when the BWR rose to 20% (Wang et al., 2023a) and the obesity model was confirmed. The results of the next 12 weeks of intervention research, in terms of BW, BWR and BWG, confirmed the weight loss effect of IO on obese mice. This is not the first report that IO has an effect on weight loss in an animal model of obesity (Yu et al., 2020; Yu et al., 2021; Hu et al., 2024), but it might be the first study of IO on weight loss and renal protection in ORG mice.

The pathogenesis of ORG is mainly related to glomerular hemodynamic changes and lipid ectopic deposition caused by obesity (Wei et al., 2021). In clinical practice, ORG is mainly characterized by asymptomatic proteinuria and its prominent pathological change is obvious glomerular hypertrophy (Wang and Baozhang, 2022).

The pathogenesis of ORG is mainly related to glomerular hemodynamic changes and lipid ectopic deposition caused by obesity (Wei et al., 2021). In clinical practice, ORG is mainly characterized by asymptomatic proteinuria and its prominent pathological change is obvious glomerular hypertrophy (Wang and Baozhang, 2022). In our study, the glomerular hypertrophy and the expression of podocyte specific proteins indicated podocyte injury but there were no significant changes in 24-h urinary protein. Pathological studies have confirmed that less than 30% podocyte damage does not cause glomerulosclerosis, which associated with the severity of CKD (Bhargava et al., 2021). This may explain why our model has not yet developed proteinuria despite podocyte injury. Proteinuria may be observed with prolonged HFD or improved assays of 24-h urinary protein. According to clinical practice, the mice podocyte injury model established in this study is regarded as an early ORG disease model (Song et al., 2023).

In addition, the apparent effects of IO in improving basement membrane thickness, fusion and disappearance of podocyte foot processes (Gong et al., 2023) as well as podocyte-specific protein



expressions in model mice suggested that IO possessed the cell biology as well as molecular biological potential to improve proteinuria in ORG. This potential was confirmed in the urine sample assay.

The relationship between increased expression of nephrin and podocalyxin and reduced proteinuria was confirmed in some

pharmacologic intervention studies (Wang Y. N. et al., 2023). Our previous study has shown that nephrin belongs to the slit diaphragm proteins and podocalyxin belongs to the apical membrane protein (Gong et al., 2023). We will continue to investigate the effects of IO on other podocyte-specific proteins such as cytoskeletal proteins (e.g., synaptophysin)



and basement membrane proteins (e.g., integrin $\alpha 3\beta 1$) in order to compensate for the shortcomings of the present experiments.

Injury-induced changes in podocyte physiology and function are a complex interaction of multiple proteins (Gong et al., 2023) that comprise the anatomical structure of podocytes at molecular levels (Lu et al., 2019). The clinical symptom of podocyte injury is proteinuria, sometimes with loss of kidney functions progressing to glomerulosclerosis (Lu et al., 2019). Our previous study showed that the presence of proteinuria in animal model is directly related to podocyte injury (Feng et al., 2024). This study suggested that podocyte injury occurred at the molecular level and had not progressed to proteinuria yet. In the present study, we also observed that IO reduced obesityinduced elevated serum TC, liver TG and FBG. In clinical diagnosis, normalization of blood glucose is one of the indicators to differentiate between ORG and DKD (Scurt et al., 2024). In our study, obesity caused significant elevation of TC and TG in the model group without significant change in blood glucose, but IO still showed a blood glucose lowering effect. The above study showed the overall modulatory effect of IO on disorders of glycolipid metabolism.

As shown by literature data, various authors have tried to determine the molecular mechanism of action of IO extracts (Szychowski et al., 2020). In our study, mechanistic



investigations revealed that the regulation of IO against ORG was closely related to TNF- α and IL-6 in the TNF signaling pathway. Several studies have recently highlighted the critical role of inflammation in ORG development. The relationship between obesity and ORG is facilitated by a network of various inflammation-associated cells (e.g., synaptophysin) and a series of inflammatory mediators (e.g., TNF- α and IL-6) (Guan et al., 2024). TNF- α and IL-6 are both small molecule proteins secreted by monocyte macrophages, which can induce apoptosis or inflammatory responses by activating different signaling pathways (Guo et al., 2019; Sethi and Hotamisligil, 2021). Our research indicated that the renoprotective effects of IO was related with it suppression on TNF- α and IL-6 levels.

On the principle that the renoprotective effects and relatedmechanism of IO had been demonstrated, our study on basis of the pharmacokinetics explored the components of IO extracts that are absorbed into the blood and had therapeutic effects on ORG. It has been shown that triterpenoids of IO could maintain the homeostasis of glycolipid metabolism (Tian et al., 2022). *In vitro* experiments showed that triterpenoids of IO had hypoglycemic effects by inhibiting α -glucosidasein (Chen et al., 2021). In addition, triterpenoids of IO could reduce the viscosity of platelets, making them more difficult to build up in the arterial wall, but also can remove free radicals in the body, play an antiinflammatory role (Duru et al., 2019; Kou et al., 2022). In particularly, trametenolic acid was described to ameliorates the progression of DKD in db/db mice via inflammation pathways (Duan et al., 2022).

When lipid metabolism is disturbed, such as in hyperlipidemic states, excess lipids accumulate under the vascular endothelium, triggering a microvascular inflammatory response. This response further promotes macrophage activation, migration, and phagocytosis of lipids, thereby accelerating the formation and accumulation of foam cells and perpetuating and exacerbating the inflammatory process (Vassiliou and Farias-Pereira, 2023). The inflammatory response promotes cellular lipid uptake and accumulation and inhibits lipid metabolism, thereby exacerbating the disruption of lipid metabolism (Wang et al., 2024). In conclusion, there is a close interaction between inflammation and lipid metabolism. Abnormalities in lipid metabolism can induce inflammation, while the inflammatory response affects the homeostasis of lipid metabolism.

5 Conclusion

In this study, we presented a network pharmacology method that incorporated UPLC-Q-TOF-MS data from IO, targetprediction databases, and human PPI, along with animal experimental validations. We demonstrated that the crucial regulation pathways and network analysis from shared targets between IO and ORG for understanding the renal protective mechanism of IO. Our research suggested that the amelioration of IO on obesity, glycolipid metabolism, proteinuria, podocyte injury in ORG mice via its modulation on TNF signal, and triterpenoids were predicated as acting components. In summary, the network pharmacology method developed here could facilitate the mechanism discovery and active compounds prediction of IO therapy and help catalyze innovation in its clinic application.

6 Prospective

Our network pharmacology studies showed that mitogenactivated protein kinase (MAPK) and STAT3 were the key targets of IO against ORG. Therefore, the perspective was



transducer and activator of transcription 3.

centered around MAPK and STAT3 in Figure 10 based on our research on TNF-a and IL-6.

TNF-a promotes inflammation and tissue injury by binding to the TNF-α receptor 1 (TNFR1) receptor (Pesce et al., 2022). TNFR1 recognizes the signaling molecule TNF-a, which in turn activates MAPK pathway cascade and induces the activation of downstream inflammatory factors (Zhao et al., 2019), thereby damaging renal podocytes. We believed that IO might reduce inflammatory response by inhibiting MAPK signaling pathway not only in DKD (Jiang et al., 2020), but also in ORG.

Receptor proteins for IL-6 include the specific IL-6 binding receptor protein (IL-6R) and gp130, which is known as a signal transduction protein (Widjaja and Cook, 2024). IL-6R binds to gp130 could activate Janus-activated kinase and STAT3. High expression of STAT3 reduce nephrin expression, contributing to podocyte apoptosis (Lei et al., 2019). The inhibition of the IL-6/ STAT3 signaling improves podocyte hypertrophy and protects podocytes (Zhou et al., 2021). We will pay our attention on the relationship between different kinds of podocyte-specific proteins and IL-6/STAT3 pathway.

At present, there are fewer reports on triterpenoid components of IO ameliorating renal inflammatory responses, but triterpenoid components, such as 3,4-dihydroxylbenzalactone, hispidin, hispolon and inotodiol from IO have been reported to inhibit TNF-induced activation of NF-κB (Zhao and Zheng, 2021).

Data availability statement

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding authors.

Ethics statement

The animal study was approved by the Ethics Review Committee for Animal Experimentation of Shanxi Provincial People's Hospital Affiliated to Shanxi Medical University. The study was conducted in accordance with the local legislation and institutional requirements.

Author contributions

ZH: Conceptualization, Data curation, Formal Analysis, Funding acquisition, Methodology, Project administration, Visualization, Writing-original draft, Writing-review and editing. LG: Conceptualization, Data curation, Formal Analysis, Methodology, Validation, Visualization, Writing-original draft, Writing-review and editing. YX: Data curation, Formal Analysis, Methodology, Writing-review and editing. RW: Data curation, Methodology, Writing-review and editing. JL: Data curation, Methodology, Writing-review and editing. XW: Data curation, Methodology, Writing-review and editing. WZ: Methodology, Writing-review and editing. HL: Conceptualization, Data curation, Formal Analysis, Funding acquisition, Project administration, Resources, Supervision, Validation, Visualization, Writing-review and editing. RL: Conceptualization, Funding acquisition, Project administration, Resources, Supervision, Writing-review and editing.

Funding

The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. This study was supported by Demonstration Project on Reformation and Quality Development of Public Hospitals (No. SCP-2023-8), the Local Science and Technology Development Funds Projects Guided by Central Government (No. YDZJSX 2021C027), Basic Research Program of Shanxi Province (No. 202103021224370) and Basic Research Program of Shanxi Province (No. 202303021222359).

Acknowledgments

The authors really appreciate Animal Experiment Center, Fifth Hospital of Shanxi Medical University (Shanxi Provincial People's

References

Anwaier, G., Wen, C., Cao, Y. N., and Qi, R. (2020). A review of the bioactive ingredients, pharmacological functions and mechanisms of inonotus obliquus. *Mini-Reviews Org. Chem.* 18, 529–538. doi:10.2174/1570193x17999200727203618

Bhargava, R., Lehoux, S., Maeda, K., Tsokos, M. G., Krishfield, S., Ellezian, L., et al. (2021). Aberrantly glycosylated IgG elicits pathogenic signaling in podocytes and signifies lupus nephritis. *JCI Insight* 6 (9), e147789. doi:10.1172/jci.insight.147789

Chen, E. Y., Tan, C. M., Kou, Y., Duan, Q., Wang, Z., Meirelles, G. V., et al. (2013). Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool. *BMC Bioinforma*. 14, 128. doi:10.1186/1471-2105-14-128

Chen, S. D., Yong, T. Q., Xiao, C., Gao, X., Xie, Y. Z., Hu, H. P., et al. (2021). Inhibitory effect of triterpenoids from the mushroom Inonotus obliquus against a-glucosidase and their interaction: inhibition kinetics and molecular stimulations. *Bioorg Chem.* 115, 105276.

Dai, Y., and Li, Y. (2011). Notes on the nomenclature of six important medicinal fungi in China. *Mycosystema* 30 (04), 515–518. doi:10.13346/j.mycosystema.2011.04.001

Daina, A., and Zoete, V. (2024). Testing the predictive power of reverse screening to infer drug targets, with the help of machine learning. *Commun. Chem.* 7 (1), 105. doi:10. 1038/s42004-024-01179-2

Duan, Q., Tian, L., Feng, J., Ping, X., Li, L., Yaigoub, H., et al. (2022). Trametenolic acid ameliorates the progression of diabetic nephropathy in db/db mice via Nrf2/HO-1 and NF- κ B-mediated pathways. *J. Immunol. Res.* 2022, 6151847. doi:10.1155/2022/6151847

Duru, K. C., Kovaleva, E. G., Danilova, I. G., and van der Bijl, P. (2019). The pharmacological potential and possible molecular mechanisms of action of Inonotus obliquus from preclinical studies. *Phytother. Res.* 33 (8), 1966–1980. doi:10.1002/ptr. 6384

Feng, Y., Liu, J., Gong, L., Han, Z., Zhang, Y., Li, R., et al. (2024). Inonotus obliquus (Chaga) against HFD/STZ-induced glucolipid metabolism disorders and abnormal renal functions by regulating NOS-cGMP-PDE5 signaling pathway. *Chin. J. Nat. Med.* 22 (7), 619–631. doi:10.1016/s1875-5364(24)60571-6

Gong, L., Wang, R., Wang, X., Liu, J., Han, Z., Li, Q., et al. (2023). Research progress of natural active compounds on improving podocyte function to reduce proteinuria in diabetic kidney disease. *Ren. Fail* 45 (2), 2290930. doi:10.1080/0886022x.2023.2290930

Guan, Y., Wei, X., Li, J., Zhu, Y., Luo, P., and Luo, M. (2024). Obesity-related glomerulopathy: recent advances in inflammatory mechanisms and related treatments. *J. Leukoc. Biol.* 115, 819–839. doi:10.1093/jleuko/qiae035

Hospital), Taiyuan, China and Nephrology Key Laboratory of Shanxi Province, Taiyuan, China.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2024.1426917/ full#supplementary-material

Guo, L., Zhang, L., Zhang, C., Tao, J., Han, X., and Ke, X. (2019). Influence of changes of PCT, IL-6 and TNF-a on organ function of patients with acute phase of chronic nephritis. *Chin. J. Nosocomiol* 29 (02), 215–218+228. doi:10.11816/CN.NI.2019-174253

Han, W., Li, M., Yang, M., Chen, S., Lu, Y., Tang, T., et al. (2023). Dietary folic acid supplementation inhibits high-fat diet-induced body weight gain through gut microbiota-associated branched-chain amino acids and mitochondria in mice. J. Nutr. Sci. Vitaminol. (Tokyo) 69 (2), 105–120. doi:10.3177/jnsv.69.105

Han, Z., Guo, L., Yu, X., Guo, H., Deng, X., Yu, J., et al. (2022). Network-driven targeted analysis reveals that Astragali Radix alleviates doxorubicin-induced cardiotoxicity by maintaining fatty acid homeostasis. *J. Ethnopharmacol.* 287, 114967. doi:10.1016/j.jep.2022.114967

Hao, J., Wang, X., Shi, Y., Li, L., Chu, J., Li, J., et al. (2023). Integrated omic profiling of the medicinal mushroom Inonotus obliquus under submerged conditions. *BMC Genomics* 24 (1), 554. doi:10.1186/s12864-023-09656-z

Hu, B., Zhou, W., Deng, X., Sun, M., Sun, R., Li, Q., et al. (2024). Structural analysis of polysaccharide from Inonotus obliquus and investigate combined impact on the sex hormones, intestinal microbiota and metabolism in SPF male mice. *Int. J. Biol. Macromol.* 262 (Pt 1), 129686. doi:10.1016/j.ijbiomac.2024.129686

Jiang, X., Zhu, Y., Ma, G., Liu, P., and Chen, L. (2023). Qualitative and quantitative analysis of major components of Renshen-Yangrong Pill by UPLC-LTQ/Orbitrap/MS and UPLC-MS/MS. *J. Pharm. Biomed. Analysis* 227, 115276. doi:10.1016/j.jpba.2023.115276

Jiang, Y., Liu, J., Zhou, Z., Liu, K., and Liu, C. (2020). Fangchinoline protects against renal injury in diabetic nephropathy by modulating the MAPK signaling pathway. *Exp. Clin. Endocrinol. Diabetes* 128 (8), 499–505. doi:10.1055/a-0636-3883

Kou, R. W., Xia, B., Han, R., Li, Z. Q., Yang, J. R., Yin, X., et al. (2022). Neuroprotective effects of a new triterpenoid from edible mushroom on oxidative stress and apoptosis through the BDNF/TrkB/ERK/CREB and Nrf2 signaling pathway *in vitro* and *in vivo*. *Food Funct.* 13 (23), 12121–12134. doi:10.1039/d2fo02854a

Kuleshov, M. V., Jones, M. R., Rouillard, A. D., Fernandez, N. F., Duan, Q., Wang, Z., et al. (2016). Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. *Nucleic Acids Res.* 44 (W1), W90-W97. doi:10.1093/nar/gkw377

Lei, X. Y., Chen, X. X., Sun, Y. H., Gao, M. D., Hu, X. X., and Suo, Y. H. (2019). Hepatitis B virus X protein decreases nephrin expression and induces podocyte apoptosis via activating STAT3. *Exp. Ther. Med.* 17 (5), 4223–4229. doi:10.3892/ etm.2019.7453

Liu, C., Yin, Z., Feng, T., Zhang, M., Zhou, Z., and Zhou, Y. (2021). An integrated network pharmacology and RNA-Seq approach for exploring the preventive effect of

Lonicerae japonicae flos on LPS-induced acute lung injury. J. Ethnopharmacol. 264, 113364. doi:10.1016/j.jep.2020.113364

Liu, S., Yuan, Y., Xue, Y., Xing, C., and Zhang, B. (2022a). Podocyte injury in diabetic kidney disease: a focus on mitochondrial dysfunction. *Front. Cell Dev. Biol.* 10, 832887. doi:10.3389/fcell.2022.832887

Liu, Y., Yang, X., Gan, J., Chen, S., Xiao, Z. X., and Cao, Y. (2022b). CB-Dock2: improved protein-ligand blind docking by integrating cavity detection, docking and homologous template fitting. *Nucleic Acids Res.* 50 (W1), W159–w164. doi:10.1093/nar/gkac394

Lu, C. C., Wang, G. H., Lu, J., Chen, P. P., Zhang, Y., Hu, Z. B., et al. (2019). Role of podocyte injury in glomerulosclerosis. *Adv. Exp. Med. Biol.* 1165, 195–232. doi:10.1007/978-981-13-8871-2_10

Mangat, G., Nair, N., Barat, O., Abboud, B., Pais, P., Bagga, S., et al. (2023). Obesityrelated glomerulopathy in children: connecting pathophysiology to clinical care. *Clin. Kidney J.* 16 (4), 611–618. doi:10.1093/ckj/sfac233

McKusick, V. A. (2007). Mendelian inheritance in man and its online version, OMIM. Am. J. Hum. Genet. 80 (4), 588–604. doi:10.1086/514346

Muthuramalingam, P., Akassh, S., Rithiga, S. B., Prithika, S., Gunasekaran, R., Shin, H., et al. (2023). Integrated omics profiling and network pharmacology uncovers the prognostic genes and multi-targeted therapeutic bioactives to combat lung cancer. *Eur. J. Pharmacol.* 940, 175479. doi:10.1016/j.ejphar.2022.175479

Nimptsch, K., Konigorski, S., and Pischon, T. (2019). Diagnosis of obesity and use of obesity biomarkers in science and clinical medicine. *Metabolism* 92, 61–70. doi:10.1016/j.metabol.2018.12.006

Pesce, B., Ribeiro, C. H., Larrondo, M., Ramos, V., Soto, L., Catalán, D., et al. (2022). TNF- α affects signature cytokines of Th1 and Th17 T Cell subsets through differential actions on TNFR1 and TNFR2. *Int. J. Mol. Sci.* 23 (16), 9306. doi:10. 3390/ijms23169306

Piñero, J., Ramírez-Anguita, J. M., Saüch-Pitarch, J., Ronzano, F., Centeno, E., Sanz, F., et al. (2020). The DisGeNET knowledge platform for disease genomics: 2019 update. *Nucleic Acids Res.* 48 (D1), D845-D855-d855. doi:10.1093/nar/gkz1021

Ren, Q., Chen, S., Chen, X., Niu, S., Yue, L., Pan, X., et al. (2022). An effective glucagon-like peptide-1 receptor agonists, Semaglutide, improves sarcopenic obesity in obese mice by modulating skeletal muscle metabolism. *Drug Des. Devel Ther.* 16, 3723–3735. doi:10.2147/dddt.S381546

Ren, Y., Wang, D., Lu, F., Zou, X., Xu, L., Wang, K., et al. (2018). Coptidis Rhizoma inhibits NLRP3 inflammasome activation and alleviates renal damage in early obesity-related glomerulopathy. *Phytomedicine* 49, 52–65. doi:10.1016/j. phymed.2018.05.019

Sandino, J., Martín-Taboada, M., Medina-Gómez, G., Vila-Bedmar, R., and Morales, E. (2022). Novel insights in the physiopathology and management of obesity-related kidney disease. *Nutrients* 14 (19), 3937. doi:10.3390/nu14193937

Scurt, F. G., Ganz, M. J., Herzog, C., Bose, K., Mertens, P. R., and Chatzikyrkou, C. (2024). Association of metabolic syndrome and chronic kidney disease. *Obes. Rev.* 25 (1), e13649. doi:10.1111/obr.13649

Sethi, J. K., and Hotamisligil, G. S. (2021). Metabolic Messengers: tumour necrosis factor. *Nat. Metab.* 3 (10), 1302–1312. doi:10.1038/s42255-021-00470-z

Shen, D., Feng, Y., Zhang, X., Liu, J., Gong, L., Liao, H., et al. (2022). In vitro immunomodulatory effects of Inonotus obliquus extracts on resting M0 macrophages and LPS-induced M1 macrophages. Evid. Based Complement. Altern. Med. 2022, 8251344. doi:10.1155/2022/8251344

Shu, L., Qiu, H., Zhang, S., Xue, J., Liu, S., Qian, J., et al. (2023). Rapid identification of chemical compositions of three species of Schisandra chinensis by ultra-high-performance liquid chromatography quadrupole-orbitrap-mass spectrometry. J. Sep. Sci. 46 (20), e2300466. doi:10.1002/jssc.202300466

Song, C., Zhang, Y., Manzoor, M. A., and Li, G. (2022). Identification of alkaloids and related intermediates of Dendrobium officinale by solid-phase extraction coupled with high-performance liquid chromatography tandem mass spectrometry. *Front. Plant Sci.* 13, 952051. doi:10.3389/fpls.2022.952051

Song, D., Zhang, A., Hu, X., Zeng, M., and Zhou, H. (2023). Wen-Shen-Jian-Pi-Hua-Tan decoction protects against early obesity-related glomerulopathy by improving renal bile acid composition and suppressing lipogenesis, inflammation, and fibrosis. *Phytomedicine* 116, 154861. doi:10.1016/j.phymed.2023.154861

Stelzer, G., Rosen, N., Plaschkes, I., Zimmerman, S., Twik, M., Fishilevich, S., et al. (2016). The GeneCards suite: from gene data mining to disease genome sequence analyses. *Curr. Protoc. Bioinforma.* 54 (1.30), 31–31.30.33. doi:10.1002/cpbi.5

Szklarczyk, D., Kirsch, R., Koutrouli, M., Nastou, K., Mehryary, F., Hachilif, R., et al. (2023). The STRING database in 2023: protein-protein association networks and functional enrichment analyses for any sequenced genome of interest. *Nucleic Acids Res.* 51 (D1), D638–d646. doi:10.1093/nar/gkac1000

Szychowski, K. A., Skóra, B., Pomianek, T., and Gmiński, J. (2020). Inonotus obliquus from folk medicine to clinical use. *J. traditional complementary Med.* 11 (4), 293–302. doi:10.1016/j.jtcme.2020.08.003

Tang, D., Chen, M., Huang, X., Zhang, G., Zeng, L., Zhang, G., et al. (2023). SRplot: a free online platform for data visualization and graphing. *PLoS One* 18 (11), e0294236. doi:10.1371/journal.pone.0294236

Tian, L., Wang, Y., Qing, J., Zhou, W., Sun, L., Li, R., et al. (2022). A review of the pharmacological activities and protective effects of *Inonotus obliquus* triterpenoids in kidney diseases. *Open Chem.* 20 (1), 651–665. doi:10.1515/ chem-2022-0168

Vassiliou, E., and Farias-Pereira, R. (2023). Impact of lipid metabolism on macrophage polarization: implications for inflammation and tumor immunity. *Int. J. Mol. Sci.* 24 (15), 12032. doi:10.3390/ijms241512032

Vecchié, A., Dallegri, F., Carbone, F., Bonaventura, A., Liberale, L., Portincasa, P., et al. (2018). Obesity phenotypes and their paradoxical association with cardiovascular diseases. *Eur. J. Intern Med.* 48, 6–17. doi:10.1016/j.ejim.2017.10.020

Wang, C., and Baozhang, G. (2022). Research progress of obesity-related glomerulopathy. *Chin. J. New Clin. Med.* 15 (10), 995–998. doi:10.3969/j.issn.1674-3806.2022.10.21

Wang, Y., Li, Z., He, J., and Zhao, Y. (2024). Quercetin regulates lipid metabolism and fat accumulation by regulating inflammatory responses and glycometabolism pathways: a review. *Nutrients* 16 (8), 1102. doi:10.3390/nu16081102

Wang, Y., Sun, Y., Tao, S., Chen, J., Qiu, Y., Xie, S., et al. (2023a). Transcriptome analysis of liver in obese mice induced by high-fat diet. *Chin. Med. Biotech.* 18 (05), 385–392. doi:10.3969/j.issn.1673-713X.2023.05.001

Wang, Y. N., Miao, H., Hua, M. R., Yang, J. Z., Pei, M., Yu, H. X., et al. (2023b). Moshen granule ameliorates membranous nephropathy by blocking intrarenal reninangiotensin system signalling via the Wnt1/ β -catenin pathway. *Phytomedicine* 114, 154763. doi:10.1016/j.phymed.2023.154763

Wei, L., Li, Y., Yu, Y., Xu, M., Chen, H., Li, L., et al. (2021). Obesity-related glomerulopathy: from mechanism to therapeutic target. *Diabetes Metab. Syndr. Obes.* 14, 4371–4380. doi:10.2147/dmso.S334199

Widjaja, A. A., and Cook, S. A. (2024). Nonspecific inhibition of IL6 family cytokine signalling by soluble gp130. *Int. J. Mol. Sci.* 25 (3), 1363. doi:10.3390/ijms25031363

Xie, Z., Bailey, A., Kuleshov, M. V., Clarke, D. J. B., Evangelista, J. E., Jenkins, S. L., et al. (2021). Gene set knowledge discovery with Enrichr. *Curr. Protoc.* 1 (3), e90. doi:10. 1002/cpz1.90

Xue, T., Zhou, L., Wang, F., Tian, Z., Li, N., Ye, T., et al. (2024). A novel method to quantify chitosan in aqueous solutions by ultrahigh-performance liquid chromatography-tandem mass spectrometry. *Carbohydr. Polym.* 329, 121758. doi:10. 1016/j.carbpol.2023.121758

Yang, Y., Jian, Y., and Liu, B. (2024). Rapid determination of diverse ganoderic acids in ganoderma using UPLC-MS/MS. *Curr. Anal. Chem.* 20, 191–200. doi:10.2174/ 0115734110289769240125115919

Yin, X., Li, M., Wang, Y., Zhao, G., Yang, T., Zhang, Y., et al. (2023). Herbal medicine formula Huazhuo Tiaozhi granule ameliorates dyslipidaemia via regulating histone lactylation and miR-155-5p biogenesis. *Clin. Epigenetics* 15 (1), 175. doi:10.1186/ s13148-023-01573-y

Yu, J., Xiang, H., and Xie, Q. (2021). The difference of regulatory effect of two Inonotus obliquus extracts on high-fat diet mice in relation to the fatty acid elongation function of gut microbiota. *Food Sci. Nutr.* 9 (1), 449–458. doi:10.1002/ fsn3.2012

Yu, J., Xiang, J. Y., Xiang, H., and Xie, Q. (2020). Cecal butyrate (not propionate) was connected with metabolism-related chemicals of mice, based on the different effects of the two Inonotus obliquus extracts on obesity and their mechanisms. *ACS Omega* 5 (27), 16690–16700. doi:10.1021/acsomega.0c01566

Zhang, Y., Liao, H., Shen, D., Zhang, X., Wang, J., Zhang, X., et al. (2022). Renal protective effects of Inonotus obliquus on high-fat diet/streptozotocin-induced diabetic kidney disease rats: biochemical, color doppler ultrasound and histopathological evidence. *Front. Pharmacol.* 12, 743931. doi:10.3389/fphar.2021.743931

Zhao, X. W., Zhou, J. P., Bi, Y. L., Wang, J. Y., Yu, R., Deng, C., et al. (2019). The role of MAPK signaling pathway in formation of EMT in oral squamous carcinoma cells induced by TNF- α . *Mol. Biol. Rep.* 46 (3), 3149–3156. doi:10.1007/s11033-019-04772-0

Zhao, Y., and Zheng, W. (2021). Deciphering the antitumoral potential of the bioactive metabolites from medicinal mushroom Inonotus obliquus. *J. Ethnopharmacol.* 265, 113321. doi:10.1016/j.jep.2020.113321

Zhou, J., Yang, J., Wang, Y. M., Ding, H., Li, T. S., Liu, Z. H., et al. (2021). IL-6/ STAT3 signaling activation exacerbates high fructose-induced podocyte hypertrophy by ketohexokinase-A-mediated tristetraprolin down-regulation. *Cell Signal* 86, 110082. doi:10.1016/j.cellsig.2021.110082